Enzymotec announces that it has received NDI status by the FDA for its novel supplement, CardiaBeat™, following earlier news that the product had passed through a self-affirmed GRAS procedure for use in food applicvations. This recent achievement, supports the company's global efforts to promote CardiaBeat™ across various market segments and industries.
CardiaBeat™ for dietary supplements is a unique ingredient, which delivers conjugated plant sterol-DHA/EPA and is capable of a simultaneous improvement of various CVD risk factors.
A recent commercial launch happened earlier this year by one of Israel's top brands, Dr. Fischer, and this achievement is expected to expand to other geographical areas shortly.
Enzymotec is an Israeli biotech company, developing and manufacturing bio-functional ingredients for the dietary supplements, functional foods and infant formula markets. Its key product categories are: SharpPS™ - phosphatidylserine for brain improvement, InFat™ - structured fat for infant formulas, which mimics mother's milk capacity to increase Calcium and energy intake and CardiaBeat™ - for reducing several CVD-risk factors simultaneously.